HK1178148A1 - Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives - Google Patents

Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives

Info

Publication number
HK1178148A1
HK1178148A1 HK13105058.3A HK13105058A HK1178148A1 HK 1178148 A1 HK1178148 A1 HK 1178148A1 HK 13105058 A HK13105058 A HK 13105058A HK 1178148 A1 HK1178148 A1 HK 1178148A1
Authority
HK
Hong Kong
Prior art keywords
methotrexate
toxicity
compositions
given
methods
Prior art date
Application number
HK13105058.3A
Other languages
English (en)
Chinese (zh)
Inventor
．卡馬利 拉希達．
Original Assignee
薩維法姆公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 薩維法姆公司 filed Critical 薩維法姆公司
Publication of HK1178148A1 publication Critical patent/HK1178148A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK13105058.3A 2007-01-18 2010-03-31 Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives HK1178148A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/655,801 US7601834B2 (en) 2005-02-22 2007-01-18 Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives

Publications (1)

Publication Number Publication Date
HK1178148A1 true HK1178148A1 (en) 2013-09-06

Family

ID=39637680

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10103311.4A HK1135618A1 (en) 2007-01-18 2010-03-31 Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives
HK13105058.3A HK1178148A1 (en) 2007-01-18 2010-03-31 Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK10103311.4A HK1135618A1 (en) 2007-01-18 2010-03-31 Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives

Country Status (10)

Country Link
US (1) US7601834B2 (es)
EP (1) EP2104502B1 (es)
JP (2) JP5916040B2 (es)
KR (1) KR20090111311A (es)
CN (2) CN102924456B (es)
AU (1) AU2008206575B2 (es)
CA (1) CA2675246C (es)
HK (2) HK1135618A1 (es)
IL (1) IL199902A (es)
WO (1) WO2008088909A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601834B2 (en) * 2005-02-22 2009-10-13 Savvipharm Inc Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives
US8415388B2 (en) * 2005-02-22 2013-04-09 Savvipharm Inc. Pharmaceutical compositions containing paclitaxel orotate
WO2010005123A1 (en) * 2008-07-07 2010-01-14 Mazence Inc. Composition for enhancing biosynthesis of hyaluronic acid or glycosaminoglycan comprising orotic acid, a salt thereof, or a derivative thereof
AU2010226442A1 (en) * 2009-03-20 2011-10-13 Antares Pharma, Inc. Hazardous agent injection system
CN108553420A (zh) * 2017-11-20 2018-09-21 平顶山学院 一种口服甲氨蝶呤脂质体及其制备方法
CN112969462B (zh) * 2018-11-12 2024-03-19 株式会社力森诺科 乳清酸衍生物的制造方法
CN112094322B (zh) * 2019-06-18 2022-04-22 首都医科大学 His-Gly-Lys修饰的甲氨蝶呤,其合成,抗肿瘤活性和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1210865B (de) * 1962-03-05 1966-02-17 Fujisawa Pharmaceutical Co Verfahren zur Herstellung des 2, 6-dioxo-tetrahydropyrimidin-4-carbonsauren Salzes des 4-Amino-5-imidazolcarbonsaeureamids
CA2128205C (en) * 1992-01-27 2004-03-30 Hiroharu Matsuoka Methotrexate derivatives
KR100400509B1 (ko) * 1995-03-27 2004-04-03 쥬가이 세이야쿠 가부시키가이샤 메토트렉세이트유도체를함유하는약제
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
ATE278399T1 (de) * 1995-07-21 2004-10-15 Savvipharm Inc Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US7601834B2 (en) * 2005-02-22 2009-10-13 Savvipharm Inc Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
US7470672B2 (en) * 2006-07-31 2008-12-30 Savvipharm Inc. Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
KR20130027576A (ko) * 2007-08-06 2013-03-15 사비팜 인크. 오로테이트 유도체를 투여하는 경우의 약물의 조직 수준을 경감시키는 조성물 및 방법

Also Published As

Publication number Publication date
CN101583362B (zh) 2013-04-17
AU2008206575A1 (en) 2008-07-24
CA2675246A1 (en) 2008-07-24
JP2014196324A (ja) 2014-10-16
US20070179145A1 (en) 2007-08-02
EP2104502A1 (en) 2009-09-30
CA2675246C (en) 2014-09-23
IL199902A (en) 2017-07-31
HK1135618A1 (en) 2010-06-11
WO2008088909A1 (en) 2008-07-24
CN102924456B (zh) 2015-03-25
CN102924456A (zh) 2013-02-13
US7601834B2 (en) 2009-10-13
AU2008206575B2 (en) 2013-02-21
JP5916040B2 (ja) 2016-05-11
CN101583362A (zh) 2009-11-18
EP2104502A4 (en) 2011-08-10
KR20090111311A (ko) 2009-10-26
JP6057947B2 (ja) 2017-01-11
IL199902A0 (en) 2010-04-15
EP2104502B1 (en) 2015-05-06
JP2010516683A (ja) 2010-05-20

Similar Documents

Publication Publication Date Title
LT2050749T (lt) Pirimidino darinys, kaip pi3k inhibitorius, ir jo panaudojimas
HK1172326A1 (en) Compounds and compositions and methods of use
IL194755A0 (en) Pyrimidine derivatives as pi3k inhibitors
TWI347321B (en) Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
IL202622A (en) Purin derivatives and pharmaceuticals containing them
IL199853A (en) Converged history of 5-Hydroxy-Admentil-2-Reindeer and Pharmaceutical Preparation containing them
IL198675A0 (en) Novel aminopyrimidine derivatives as plk1 inhibitors
HK1123296A1 (en) Pyrazine derivatives and use as pi3k inhibitors
HK1135618A1 (en) Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives
IL192580A0 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
EP2001338A4 (en) FURNITURE
EP2024272A4 (en) AMID DERIVATIVES AS ION CHANNEL NIGANDS, AND PHARMACEUTICAL COMPOSITIONS AND USER METHOD THEREFOR
SI1917218T1 (sl) Sestavki delno deacetiliranih hitinskih derivatov
PL2200429T3 (pl) Kompozycje olejku cytrusowego i sposoby stosowania
IL200576A0 (en) Inhibitors of rtp801 and their uses
ZA201000992B (en) Anti-viral compounds, compositions, and methods of use
HK1210948A1 (en) Methotrexate adjuvants to reduce toxicity and methods for using the same
IL196594A0 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
SG10201510301UA (en) Compositions incorporating sesamin-class compounds and vitamin b1 class compounds
ZA200808190B (en) Malonamide derivatives as gamma secretase inhibitors
ZA200900416B (en) Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
PL2043661T3 (pl) Zastosowanie tylwalozyny jako środka przeciwwirusowego
EP2076281A4 (en) STABILIZING ALKYLGLYCOSIDIC COMPOSITIONS AND METHODS THEREOF
IL186606A0 (en) Compositions and uses of amooranin compounds
GB2452142A8 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the sa

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220118